Try our Advanced Search for more refined results
Health
-
April 10, 2026
Mich. Care Staff Not Paid For Working Meal Breaks, Suit Says
A former senior care facility employee has filed a proposed Fair Labor Standards Act collective action in Michigan federal court, claiming the assisted living and memory care center shortchanged hourly workers on overtime in two ways — by automatically deducting meal breaks they spent working and by excluding bonus pay from their regular rate.
-
April 10, 2026
Philip Morris Urges 11th Circ. To Affirm FDA Rule Toss
Philip Morris urged the Eleventh Circuit to affirm a decision that struck down a U.S. Food and Drug Administration rule calling for graphic warnings on cigarette packaging, arguing a district court rightly found the FDA had not followed proper procedure when crafting the regulations.
-
April 10, 2026
Feds Say Pot Opponents Lack Injury In CMS Hemp Suit
Federal health regulators have urged a D.C. federal judge to toss a bid by anti-cannabis activists to block a program to ease access for Medicare beneficiaries to federally legal hemp products that have small amounts of THC.
-
April 10, 2026
Drugmakers Can Intervene In Texas, Fla. Abortion Drug Suit
A federal judge Friday allowed abortion medication manufacturers GenBioPro Inc. and Danco Laboratories to intervene in litigation brought by the states of Texas and Florida seeking to undo a slew of federal regulations concerning the abortion drug mifepristone.
-
April 10, 2026
Elevance Can't Nix Suit Over GLP-1 Coverage For Sleep Apnea
An Indiana federal judge declined to toss a proposed class action claiming Elevance Health Inc. illegally denied coverage for a GLP-1 weight loss medication that was prescribed to treat sleep apnea, ruling that the insurance company is the right party to answer to the allegations at play.
-
April 10, 2026
Taxation With Representation: Goodwin, CMS, Wilson Sonsini
In this week's Taxation With Representation, Gilead Sciences Inc. acquires clinical-stage biotechnology company Tubulis GmbH, private equity firm Court Square Capital Partners closes a multibillion-dollar fund and Neurocrine Biosciences Inc. buys rare-disease drugmaker Soleno Therapeutics Inc.
-
April 10, 2026
Ill. Jury Adds $17M Punitive Award To Baby Formula Verdict
Illinois jurors on Friday slapped another $17 million in punitive damages atop the $53 million they awarded the previous afternoon to four mothers who accused Abbott Laboratories of selling preterm infant formula that contributed to a serious and often fatal gut condition their babies developed.
-
April 10, 2026
UK Litigation Roundup: Here's What You Missed In London
The past week in London has seen the owner of an oil tanker stuck in the Strait of Hormuz sued by an energy company and an insurer, law firm Boodle Hatfield LLP and two Serle Court barristers sued by a group of Winston Churchill's great-grandchildren, and Welsh Water hit with a fresh class action over polluted rivers.
-
April 10, 2026
US Outpaces Global M&A Amid 'Made In America' Push
U.S. companies were a major driver of a global M&A rebound in the first quarter of 2026, with domestic dealmaking surging to its strongest start in four years and outpacing global growth amid lower borrowing costs and a "Made in America" policy push, according to a first-quarter Mergermarket report.
-
April 09, 2026
Yale Medical School Can't Nix Fraudulent Insemination Suit
Yale can't escape a negligence suit by onetime patients alleging its former fertility doctor secretly inseminated them with his own sperm, after a Connecticut judge said that a letter from an anonymous doctor, which is mandated by law to support their claims, met the statutory requirements.
-
April 09, 2026
Swiss Firm Says Clause Required Zurich Hospital Arbitration
A D.C. federal judge is being called upon to again enforce a roughly $8.6 million arbitral award issued against Equatorial Guinea in a dispute over an ill-fated hospital operating contract, months after his initial enforcement ruling was overturned by the D.C. Circuit.
-
April 09, 2026
Clinic Charged Patients For Faulty Mammograms, Suit Claims
A West Virginia clinic provided "worthless" mammograms to hundreds of patients for more than two years, according to a proposed class action filed in federal court which seeks refunds and other damages in excess of $5 million.
-
April 09, 2026
Irish Mallinckrodt Unit Stuck In Drug Price-Fixing Suit
An Irish entity of drugmaker Mallinckrodt waited too long to seek dismissal of a price-fixing lawsuit brought by states based on a lack of personal jurisdiction or proper service, a Connecticut federal judge has ruled, finding that the company first raised that argument more than five years after the complaint was filed.
-
April 09, 2026
Cigna 401(k) Suit Won't Wait For Intel Supreme Court Decision
A Pennsylvania federal court turned down Cigna's bid to stay a proposed class action alleging the insurance company misspent forfeitures from its employee 401(k) plan and offered an underperforming investment fund while the U.S. Supreme Court considers a 401(k) suit against Intel, finding the request unjustified.
-
April 09, 2026
Abbott Hit With $53M Verdict Over Baby Formula Harms
A Cook County jury on Thursday awarded a total of $53 million in damages to four mothers claiming Abbott Laboratories' preterm baby formula contributed to their babies' development of a serious and often fatal gut condition, in the first of such claims to go to trial in Illinois.
-
April 09, 2026
Medical Practice Hit With $49M Verdict Over Missed Cancer
A Connecticut jury on Thursday awarded a $49 million verdict against The Westchester Medical Group PC, finding the entity liable after a high-risk patient accused her gynecologist of failing to properly screen her while cervical cancer spread through her chest, abdomen and pelvis.
-
April 09, 2026
Split 4th Circ. Backs West Virginia Schoolchildren Vax Law
A split Fourth Circuit panel struck down an order barring West Virginia from applying a compulsory vaccination law to a student whose parents alleged the law violates her religious rights, ruling the law serves the state's interest in reducing the spread of infectious diseases.
-
April 09, 2026
Merck Beats 295 Zostavax Suits Over Missed Deadlines
A Pennsylvania federal judge has tossed 295 cases against Merck & Co. Inc. in the multidistrict litigation alleging its Zostavax shingles vaccine caused the disease, with the court reasoning that the plaintiffs' inactivity doomed the cases.
-
April 09, 2026
Doctor Who Sued Biotech Co. Over Arrest Wins $58M Verdict
A Georgia jury has handed a $58 million verdict to a retired Stanford University medical school professor who accused a Peach State biotech firm of conspiring to have him criminally charged in a failed bid to avoid paying him millions in product design commissions.
-
April 09, 2026
Pest Co. Can't Eradicate Workers' Suit Over Tobacco Fees
Pest control company Rentokil can't escape a proposed class action alleging it unlawfully charged tobacco users more for health benefits without providing a reasonable way to avoid the fee, with a Pennsylvania federal judge rejecting the company's argument that decade-old regulations were invalid.
-
April 09, 2026
Kirkland-Led Court Square Capital Raises $3.8B
Kirkland & Ellis LLP-advised private equity shop Court Square Capital Partners on Thursday announced that it wrapped its fifth fund with roughly $3.8 billion of capital commitments, marking the firm's largest fundraise to date.
-
April 09, 2026
Philly Injection Site Row Judge Rejects Nonprofit's 'Ploy'
A Pennsylvania federal judge on Thursday called the addition of overdose prevention nonprofit Safehouse's president as a counterclaim plaintiff in the government's suit to stop it from launching a safe-injection site in Philadelphia a "ploy" to add another to the ranks of those claiming the government infringed the group's religious freedom.
-
April 15, 2026
The 2026 Lawyer Satisfaction Survey: Where Do You Stand?
How is your work-life balance? Are you content with your compensation and opportunities for advancement at work? Take the 2026 Law360 Lawyer Satisfaction Survey and share your thoughts.
-
April 09, 2026
Ex-Pharmacy Director Denies Using Trade Secrets At New Job
A former director at a specialty infusion therapy pharmacy urged a New Jersey federal court to reject her former employer's bid to block her from working for a rival, arguing that her new job does not pose any threat of imminent harm to her former company.
-
April 09, 2026
Feds Cast Calif. Tribe's Opioid Clinic Fight As Money Grab
The federal government says it had justification for rejecting a California tribe's request for an agreement to fund an opioid treatment center, claiming that a challenge over the denial is more about trying to monetize on advantages available to Indigenous nations and less about helping patients.
Expert Analysis
-
What We Know About DOJ's New FCA Enforcement Priorities
Recent remarks from the leader of the Justice Department’s commercial litigation branch provide key insights on how False Claims Act cases — especially healthcare fraud, trade fraud, antidiscrimination and cybersecurity claims — will be evaluated, prioritized and pursued as heightened enforcement becomes the new normal, say attorneys at Latham.
-
The Benefits Of Choosing A Niche Practice In The AI Age
As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.
-
How PBMs Can Adapt To Plan Sponsors' Disclosure Demands
As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.
-
How To Engage With Gov't's Direct-To-Consumer Drug Policy
The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.
-
Opinion
It's Time To Clarify California's Elder Abuse Act
As California's elderly population soars, the Golden State's high court and Legislature must provide needed clarification about the scope of the Elder Abuse Act, to resolve the inconsistencies and ambiguities that have impeded the law's ability to remedy elder abuse, neglect and abandonment, say attorneys at Horvitz & Levy.
-
Series
Podcasting Makes Me A Better Lawyer
Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.
-
When Fraud Involvement Disqualifies FCA Whistleblowers
A Massachusetts federal court's recent dismissal of a False Claims Act relator in U.S. ex rel. Perry v. First Psychiatric Planners provides instructive insight into when whistleblowers may be denied their share of settlement proceeds, even if their involvement in the underlying fraud is a step removed, say attorneys at Holland & Knight.
-
Job Shift Accommodation Ruling Clarifies 'Essential Function'
In Siebrecht v. Mercy Health-Iowa, the Eighth Circuit's recent denial of a disabled worker's shift exemption request shows that the essential function of a job can encompass more than core job requirements and include things like scheduling flexibility, says Kim Kirn at Miles Mediation & Arbitration.
-
Opinion
Fed. Circ. Must Bury Design Patent Doctrinal Zombies
After recently finding noninfringement in Range of Motion Products v. Armaid, the Federal Circuit must rehear the case to confront two troublesome doctrines of design patent law claim construction — feature filtration and claim verbalization — that have lingered for decades and intensified in recent years, say attorneys at McAndrews Held.
-
H-1B Registration Tips For New Wage-Weighted Selection
Practitioners participating in this year’s H-1B visa registration, currently underway, must understand that under the new wage-weighted selection process that replaced the random lottery, the crucial first step is choosing the correct standard occupational classification, says Jimmy Lai at Lai & Turner.
-
Lessons From Justices' Split On Major Questions Doctrine
The justices' varied opinions in Learning Resources v. Trump, which held the International Emergency Economy Powers Act did not confer the power to impose tariffs, offer a meaningful window into the U.S. Supreme Court's perspective on the major questions doctrine that will likely shape lower courts' approach to executive action challenges, say attorneys at Venable.
-
Drug Wholesaler's DPA Shows Imperfect Efforts Still Count
Atlantic Biologicals’ recent deferred prosecution agreement with federal prosecutors for allegedly distributing controlled substances to pill mill pharmacies demonstrates that even subpar cooperation, when combined with genuine remediation and strategic advocacy, can yield outcomes that protect a company's long-term interests, says Jonathan Porter at Husch Blackwell.
-
Key Takeaways As HRSA Aims To Revive 340B Rebate Pilot
The U.S. Department of Health and Human Services' recent request for feedback on the 340B Rebate Model Pilot Program demonstrates that it intends to correct the model's procedural defects, which is positive news for participating manufacturers, but a setback for covered entities, say attorneys at Manatt.
-
Why Mukherji Won't End USCIS' EB-1A Two-Step
A Nebraska federal court's recent decision in Mukherji v. Miller seemed to vindicate longstanding complaints about the U.S. Citizenship and Immigration Services' controversial two-step adjudication process, declaring the framework unlawful — but Mukherji is unlikely to be the death blow that immigration practitioners have hoped for, says Jun Li at Reid & Wise.
-
Unique Issues Facing Brand-Compounder Patent Litigation
Recent litigation and potential enforcement action against Hims & Hers Health raise questions about how compounders and branded pharmaceuticals companies would be positioned in patent litigation as compared to generics companies, which would require strategies different from those that would be used in traditional Hatch-Waxman Act litigation, say attorneys at Morgan Lewis.